Daily vs Intermittent Antituberculosis Therapy for Pulmonary Tuberculosis in Patients With HIV

Narendran, Gopalan; Santhanakrishnan, Ramesh; Natarajan Palaniappan, Alangudi; A. Menon, Pradeep; Lakshman, Sekar; Padmapriyadarsini, Chandrasekaran; Narayan Sivaramakrishnan, Gomathi; Reddy, Devarajulu; Perumal Kannabiran, Bhavani; Kumar Kupparam Agiboth, Hemanth; Vijay, Krishnamoorthy; Sridhar, Rathinam; Chockalingam, Chandrasekar; Manoharan, Tamizhselvan; Ayyamperumal, M.; Jayanthi, Nalini; Satagopan, Kumar; Narayanan, Ravichandran; Krishnaraja, Raja; Sekar, Sathiyavelu; Kesavamurthy, Bhanu; Suresh, Chandra; Selvachitiram, Murugesan; Arasan, Gunasundari; Susaimuthu, Stella; Rathinam, Prabhakaran; Angamuthu, Prabhakar; Jayabal, Lavanya; Murali, Lakshmi; Ramachandran, Ranjani; Tripathy, Srikanth; Swaminathan, Soumya

doi:10.1001/jamainternmed.2018.0141

Public

Daily vs Intermittent Antituberculosis Therapy for Pulmonary Tuberculosis in Patients With HIV

Published in JAMA Internal Medicine • Mar 5, 2018

Authors:

Gopalan Narendran

Ramesh Santhanakrishnan

Alangudi Natarajan Palaniappan

Abstract

Importance: The benefit of daily over thrice-weekly antituberculosis therapy among HIV-positive patients with pulmonary tuberculosis (TB) who are receiving antiretroviral therapy remains unproven. Objective: To compare the efficacy and safety of daily, part-daily, and intermittent antituberculosis t...

Subject

Medicine

Interquartile range

Sputum

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!